Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Investing Activities (2021 - 2024)

Historic Cash from Investing Activities for InMed Pharmaceuticals (INM) over the last 4 years, with Q1 2024 value amounting to -$2.0.

  • InMed Pharmaceuticals' Cash from Investing Activities rose 9999.84% to -$2.0 in Q1 2024 from the same period last year, while for Jun 2024 it was -$161806.0, marking a year-over-year increase of 8183.62%. This contributed to the annual value of -$9293.0 for FY2024, which is 9859.58% up from last year.
  • InMed Pharmaceuticals' Cash from Investing Activities amounted to -$2.0 in Q1 2024, which was up 9999.84% from -$33606.0 recorded in Q2 2023.
  • InMed Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $306011.0 during Q4 2021, with a 5-year trough of -$725457.0 in Q2 2022.
  • For the 4-year period, InMed Pharmaceuticals' Cash from Investing Activities averaged around -$119257.9, with its median value being -$33606.0 (2023).
  • In the last 5 years, InMed Pharmaceuticals' Cash from Investing Activities tumbled by 350816.21% in 2023 and then skyrocketed by 9999.84% in 2024.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Cash from Investing Activities stood at $306011.0 in 2021, then tumbled by 337.07% to -$725457.0 in 2022, then soared by 95.37% to -$33606.0 in 2023, then skyrocketed by 99.99% to -$2.0 in 2024.
  • Its last three reported values are -$2.0 in Q1 2024, -$33606.0 for Q2 2023, and -$128198.0 during Q1 2023.